Can telehealth boost HIV prevention in underserved communities?
NCT ID NCT05528653
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether offering HIV PrEP (a daily pill that prevents HIV) through telehealth visits could help more Black and Latino men who have sex with men start and stay on the medication. Researchers enrolled 75 HIV-negative men and provided PrEP care remotely. The goal was to see if removing the need to visit a clinic in person would increase uptake and continuation of PrEP in these communities.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Descovy (HIV PrEP drug)
- What this could lead to
- If successful, this approach could make HIV prevention more accessible for Black and Latino men who have sex with men, reducing new infections.
- What could go wrong
- This is a small, completed Phase 4 study (75 participants) without a control group, so results may not apply broadly. Telehealth may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
75 people
The number who actually took part.
- Started
-
Jul 2022
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. HIV negative on any FDA approved HIV test within 10 days of starting PrEP 18 years and older 2. No medical or mental health comorbidity that would preclude participating in a clinical study as deemed by the study investigator 3. Able to understand and sign consent in English or with other language interpreter 4. Able to stay in the state catchment area of the license health care provider 5. No use of PrEP for more than 30 days in the last year Exclusion Criteria: 1. HIV positive 2. If greater and equal to 50 years of age and Renal Glomerular Filtration Rate (GFR) \<30 mg/g 3. \<18 years of age 4. No access to Internet or devise for telehealth 5. Cis-gender Women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV prevention are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vivent Health
Denver, Colorado, 80245, United States
-
Vivent Health
St Louis, Missouri, 63103, United States
-
Viventh Health
Milwaukee, Wisconsin, 53203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pharmacist chat group help stop HIV?
- A monthly ring could put HIV prevention in Women's hands
- Can a conversation prevent HIV? study tests In-Person vs. online counseling for PrEP uptake
- Could a simple app help pharmacists stop HIV?
- New counseling approach aims to boost HIV prevention in young black men who have sex with men
- New HIV vaccine strategy aims to prime and boost immune defenses